Introduction
Cholesterol is an essential component of mammalian cell membranes and serves as a precursor for bile acids and various endocrine steroid hormones. The biosynthesis, cellular absorption, and efflux of cholesterol are tightly regulated to maintain homeostatic levels required for normal cell proliferation. A link between cholesterol and cancer was proposed over a century ago, with the discovery that tumor cells had accumulated cholesterol [
1]. Since then, many studies have provided evidence for a link between carcinogenesis/tumor progression and cholesterol biosynthesis and efflux [
2]. Elevated activity of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the first enzyme of the mevalonate pathway, has been shown in a range of different tumors including hepatocellular carcinoma [
3], leukemia [
4] and lymphoma [
5]. Moreover, inhibition of HMGCR, the initial and rate-limiting step of cholesterol biosynthesis, with statins inhibits tumor growth in mouse xenograft models [
6‐
8]. Epidemiological data further support a role for statins in reducing the risk of developing pancreatic cancer [
9] and with an increased progression-free survival in inflammatory breast cancer [
10].
Cancer is a clonal disease whereby therapeutic intervention poses a selective pressure resulting in cancer cells escaping therapy. Surviving cells are characterized by drug resistance and are often associated with disease relapse [
11]. Several reports support a function of cholesterol in establishing and maintaining increased drug tolerance in cancer cells. Cholesterol has been found to be increased by 50 % in isolated plasma membranes of vinblastine-resistant versus sensitive acute lymphoblastic leukemia cells (ALL) [
12]. The observation that drug-resistant myeloid leukemia cell lines are more sensitive to statins than their sensitive parental lines further substantiates a role for cholesterol in chemoresistance [
13]. Moreover, in vitro treatment of acute myeloid leukemia (AML) cells with chemo- or radiotherapy causes increased intracellular cholesterol levels accompanied by an increased drug tolerance, whereas inhibition of cholesterol biosynthesis with statins could restore drug sensitivity [
14]. Further, it has been shown that rat and human hepatocellular carcinoma cells display increased mitochondrial cholesterol levels and HMGCR or squalene synthase (FDFT1) inhibition sensitizes those cells to mitochondria-directed chemotherapy [
15]. Similarly, in a doxorubicin-resistant bladder cancer cell line, simultaneous administration of statin with doxorubicin reverted the resistant phenotype [
16].
We have recently shown that resistance to daunorubicin (DNR) in an ALL cell line is associated with a rewired metabolism [
17]. RNA Sequencing revealed the cholesterol biosynthetic pathway as the top canonical pathway up-regulated in the resistant cells [
17].
In the present study, we validate these previous findings using quantitative real-time PCR (RT-qPCR) and measure relative quantity and synthesis rates of cholesterol itself and lanosterol, the first committed intermediate in cholesterol biosynthesis, by application of 2H2O labelling and mass spectrometry isotopomer analysis. We found that the transcriptional up-regulation of the cholesterol biosynthesis pathway does not translate into an increased cholesterol synthesis rate or quantity in the resistant cells, but rather an increased flux through the lanosterol pool. With this report we shift the focus from the importance of solely cholesterol for cancer progression and drug sensitivity to the upstream biosynthetic intermediate lanosterol. Our data reveal a previously unrecognized metabolic cost of cancer drug resistance and point toward a potential novel regulatory role of lanosterol in maintaining cholesterol homeostasis, which may be particularly critical for drug-resistant leukemia cancer cells.
Materials and methods
Cell lines and growth conditions
CCRF-CEM [CCRF CEM] (ATCC
® CCL-119™) (CEM) leukemia cells were acquired through LGC Standards (Teddington, UK) from the American Type Culture Collection and maintained following the recommendations from ATCC. Detailed description of the generation of the DNR-resistant CEM/R2 is described in [
17].
Proliferation assays: ATPlite™ (Perkin Elmer)
Cells were seeded in black plates with a final density of 15,000 cells/well. Simultaneously, the respective treatment was started. ATPlite™ was performed following the manufacturer’s instructions. Cells were incubated for 48 h with or without cholesterol biosynthesis inhibitors, namely, atorvastatin (100 µM), terbinafine (25 µM), ketoconazole (20 μM), triparanol (2 µM), CI976 (25 µM), all purchased from Sigma-Aldrich (MO, USA), and hymeglusin (10 µM), YM-53601 (10 µM) and BIBB-515 (25 µM) all ordered from Santa Cruz Biotechnology (TX, USA) in the absence (vehicle control DMSO or MeOH) or presence of DNR (CEM, 1 nM and CEM/R2, 0.5 μM) in RPMI 1640 (HyClone, Fisher scientific) supplemented with 10 % FBS.
Lanosterol, cholesterol, and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (PC), all obtained from Sigma-Aldrich (MO, USA), were dissolved in chloroform/methanol (1:1). Cholesterol or lanosterol was mixed in equimolar proportion with PC and dried by vacuum in a speed vacuum concentrator. The lanosterol/PC, cholesterol/PC mixture, or PC alone was re-suspended in serum-free RPMI 1640 on the day of the experiment and used within the day of preparation.
To analyze the effect of lanosterol and cholesterol, cells were incubated in serum-free RPMI 1640 medium (HyClone, Fisher scientific) for 48 h in the absence or presence of DNR (CEM, 100 nM and CEM/R2, 1 μM). The negative/vehicle control always contained respective amounts of DMSO, MeOH, or PC.
RNA isolation, reverse transcription, and quantitative real-time PCR
One million cells of each CEM and CEM/R2 cells were seeded in a 6-w plate and cultured for 24 h in RPMI supplemented with 10 % FBS without or with 50 µM atorvastatin, 12.5 µM terbinafine, 12.5 µM BIBB515, or 10 µM ketoconazole before harvested for RNA preparation. Total RNA isolation was performed using RNeasy
® Mini Kit (Qiagen, Germany) following manufacturer’s instructions. RNA (1 µg) was treated with DnaseI (NEB) prior reverse transcription using iScript™ cDNA Synthesis Kit (Bio-Rad) following the manufacturer’s instructions. The qPCR was set up using iTaq™ Universal SYBR
® Green Supermix (Bio-Rad), and real-time PCR and data collection were performed on Bio-Rad
®iQ™5 Real-Time PCR Detection System. Primer design procedure and detailed description of each step can be found in [
18]. All qPCR primer pairs are stated in Table S1. Expression of gene-encoding proteins involved in cholesterol biosynthesis was normalized to the reference genes RPL13A, RPS18, ACTB, and GAPDH.
Liquid chromatography–mass spectrometry (LC–MS) measurements
For experiments with 2H2O, 1 × 106 cells were cultured for 4 h (without or with 50 µM atorvastatin, 12.5 µM terbinafine, 12.5 µM BIBB515 or 10 µM ketoconazole) or 24 h (untreated comparison of lanosterol and cholesterol turnover in CEM versus CEM/R2), in RPMI 1640 medium supplemented with 10 % FBS which was either diluted with sterile H2O or 2H2O (99 %) to a final concentration of 30 % 2H2O (Cambridge Isotope Laboratories (MA, USA)).
The cells were centrifuged, washed at least once with PBS, transferred to an 1.5-mL Eppendorf tube and lysed/extracted using 200 μL 50:50 chloroform/methanol to which a small lab spoon of 0.2 μm i.d. glass beads was added (Retsch). Tubes were placed in a Retsch Beadmill MM 400 and shaken at 30 Hz for 2 min. Eppendorf tubes were transferred to a centrifuge kept at 4 °C and spun at 14,000 rpm for 10 min after which the supernatant was transferred to LC–MS glass vials, dried down in a speed vacuum concentrator, and stored at −20 °C until analysis. Samples were dissolved in 20 μL chloroform out of which 2–4 μL were injected into the Agilent 1290 LC system connected to either a 6540 or 6550 Agilent Q-TOF mass spectrometer (CA, USA) and an atmospheric pressure ionization (APCI) source was used. Data were collected between m/z 70 and 1700 in positive ion mode only. The following APCI settings were used: gas temperature 200 °C, vaporizer 350 °C, gas flow 11 l/min, nebulizer pressure 40 psig, Vcap 3500, corona 4, fragmentor 100, Skimmer1 45, and OctapoleRFPeak 750. All samples were separated using reverse phase only, Kinetex C18, 100 mm × 2.1 mm, 2.6 μM 100 Å, Phenomenex (CA, USA). For elution, solvents reversed phase (A) H2O, 0.1 % formic acid (B) 75:25 methanol/isopropanol, 0.1 % formic acid were used. All solvents were of HPLC grade. Linear gradients were used for all separations and were devised as follows for reversed phase separation (0.5 mL/min) min 0: 5 %B, min 8: 95 %B, min 10: 95 %B, min 10.2: 5 %B, min 12: 5 %B. Raw data were processed and analyzed using MassHunter Qual, Agilent (CA, USA). Identification of metabolites in all experiments was carried out using synthetic standards obtained from Sigma-Aldrich (MO, USA) and Inventia Pty. Ltd (NSW, Australia) comparing accurate mass, retention time, and in some cases MS/MS spectra.
Discussion
An altered cholesterol metabolism is critical for rapidly proliferating cancer cells and plays a role in development of resistance. Based on our findings, we suggest that lanosterol, the first intermediate committed solely toward cholesterol biosynthesis, is a valuable marker to detect alterations of the cellular cholesterol homeostasis. We show that the increased lanosterol flux in a DNR-resistant daughter cell line of the T-ALL leukemia cell line CEM represents a metabolic cost that can potentially have therapeutic implications. In a broader sense, our results highlight that phenotyping cancers with respect to cholesterol metabolism can be useful for therapy guidance.
We used RT-qPCR and compared mRNA levels of all proteins involved in the cholesterol biosynthesis pathway (Fig.
1a) between DNR-sensitive CEM cells and the resistant daughter cell line CEM/R2. The almost uniformly increased expression in the resistant cells (Fig.
1b) was not matched by increased levels of cholesterol or lanosterol (Fig.
2a). Using
2H
2O labelling of cultured cells, we could demonstrate an increased biosynthetic flux of lanosterol (Fig.
2b, c) with no concomitant accumulation of lanosterol or cholesterol (Fig.
2a). It is therefore reasonable to assume that in CEM/R2 cells the increased lanosterol production reflects that lanosterol, rather than just being an intermediate in the cholesterol biosynthesis, is exported out of the cell [
32‐
34] or fills another function. Membrane associated lanosterol will alter plasma membrane organization relative to cholesterol [
35], which potentially could impact drug tolerance [
12]. Further, lanosterol has been proposed to act as a survival factor for dopaminergic neurons, potentially via a mitochondrial decoupling mechanism [
36]. We observed that exogenously applied lanosterol negatively affected viability of resistant cell but had a positive effect on cell viability of DNR-sensitive CEM cells.
Moreover, since lanosterol has been described as a survival factor [
36], we tested the effect of lanosterol on DNR sensitivity of both CEM and CEM/R2 by co-administration of DNR and lanosterol, which revealed that lanosterol presence decreased DNR sensitivity of CEM cells but had no such effect on CEM/R2 cells. We conclude from the results from all those experiments that the increased lanosterol flux is a stressor for the resistant cells and thus a negative consequence of the resistance. Consequently, it is reasonable to hypothesize that resistant cells have different regulatory mechanisms of the cholesterol biosynthetic pathway to cope with the increased lanosterol flux. Inhibition of different steps of the cholesterol pathway revealed differential effects on viability when comparing sensitive and resistant cells (Fig.
3a). Further, using
2H
2O labelling mass spectrometry, we show that inhibitors that reduce the lanosterol synthesis rate more in the resistant cells affected their viability less upon treatment with the respective inhibitors (Fig.
3b, c).
Lanosterol itself has been shown to be involved in posttranslational regulation of the cholesterol biosynthesis pathway through induction of proteasomal degradation of HMGCR [
37] and SQLE [
38]. The enzyme SQLE, which is inhibited by terbinafine, is further transcriptionally [
39,
40] and posttranslationally regulated by cholesterol [
41,
42] and participates, together with LSS, which can be inhibited by BIBB515, in a shunt of the mevalonate pathway that produces 24,25-EC (Figs.
1a,
4a). By measuring gene expression of all genes in the cholesterol biosynthesis when applying one of the inhibitors, atorvastatin, terbinafine, BIBB515, or ketoconazole, a pattern emerged. Inhibitors of SQLE or LSS, both of which are enzymes involved in the main pathway and in the 24,25-EC shunt pathway, resulted in a reciprocal expression pattern for many genes when comparing CEM versus CEM/R2. In contrast, atorvastatin and ketoconazole that do not affect the 24,25-EC shunt pathway exert the same effects on mRNA levels of cholesterol biosynthesis genes in both sensitive and resistant cells (Figs.
4b, S2).
In conclusion, our data provide a novel connection between drug resistance and increased lanosterol flux and also links the 24,25-EC shunt pathway with resistance. We believe that there is a high potential for exploitation of this knowledge in personalized therapy guidance.